Thymosin Alpha-1: The Immune Peptide Hiding in Plain Sight
A pseudonymous reader walks through decades of human RCT data on the most evidence-rich immune peptide nobody in the US biohacker scene seems to talk about.
by JoyBoy
12 min read
Last reviewed May 2026
🟢 Human RCT
Not FDA approved in the US. Approved in 35+ countries (Zadaxin).
Why I looked into this
I went looking for Thymosin Alpha-1 because it kept not coming up. Every list of “trending peptides” in 2026 names the same handful. BPC-157, TB-500, GHK-Cu, the GLP-1 family, MOTS-c. Thymosin Alpha-1 sits there with a marketing approval in 35+ countries, a generic name (Zadaxin), and decades of Phase 3 work, and it gets less airtime than peptides with zero published human trials.
That gap got my attention. The most evidence-rich immune peptide on the market is also the quietest. I wanted to know why.
The short answer, after reading the literature, is that the evidence is genuinely solid and genuinely boring. It does not promise to make you younger. It does not promise to fix your shoulder in a week. It modulates immune function in patient populations where the immune system is failing, and the effect sizes are real but modest. Boring evidence does not sell newsletters.
What Thymosin Alpha-1 actually is
Thymosin Alpha-1 is a 28-amino-acid synthetic peptide. Its sequence is identical to a fragment of a naturally occurring peptide produced by the thymus, the small organ behind the breastbone that trains your T cells. The thymus shrinks across the lifespan, and the peptide fragments it produces are part of the signaling that keeps T-cell immunity calibrated.
The synthetic version, marketed internationally as Zadaxin by SciClone Pharmaceuticals, was developed in the 1970s and 1980s and entered clinical research seriously in the 1990s. Approved indications outside the United States include chronic hepatitis B, adjuvant use in certain cancer regimens, and select immune-compromised patient settings such as severe sepsis and post-surgical immune support. Different countries approve it for different things, but the through-line is the same: it is positioned as an immune modulator in patients whose immune function is impaired.
What the human research shows
Do published human trials actually exist?
Yes, and there are a lot of them. Thymosin Alpha-1 has multiple Phase 3 randomized controlled trials, many published in mainstream journals, going back roughly three decades. The strongest evidence base is in chronic hepatitis B, where the endpoint is sustained virologic response (a measurable reduction in viral load that holds after the active phase of the trial). Beyond hepatitis B, the published human work spans vaccine-response augmentation in older adults, immune support during cancer regimens, and immune modulation in severe sepsis and (more recently) COVID-related critical illness.
What evidence actually exists, and what does it show?
The strongest signal is in chronic hepatitis B. A meta-analysis by Yang et al (Antivir Ther, 2008) pooled five RCTs and reported a sustained virologic response rate roughly twice that of untreated controls at 12 months post-trial. More recent analyses have added trials and refined the estimate, but the directional finding has held up. The effect is modest in absolute terms, larger relative to placebo, and most pronounced in HBeAg-positive patients.
Quick summary of the key trial threads I read:
- Chronic hepatitis B (multiple Phase 3 trials, 1990s through 2010s): sustained virologic response endpoints, several positive trials, used as monotherapy and as adjuvant alongside interferon. This is the indication that earned the international approvals.
- Vaccine-response augmentation (older adults, multiple smaller RCTs): antibody titers after influenza vaccination higher in the active arm than placebo in several published studies. Effect size modest. Population specifically older adults whose vaccine response is known to be blunted.
- Severe sepsis (Liu et al, Crit Care, 2013, n=361): 28-day mortality numerically lower in the active arm, statistically borderline. Follow-up trials have produced mixed results.
- COVID-19 critical illness (multiple observational and small RCT publications, 2020 to 2022): mixed quality, some positive signals on lymphocyte recovery and clinical course, no definitive Phase 3 result. The signal was interesting enough to keep generating trials.
- Cancer adjuvant settings (various, mostly outside the US): used alongside chemotherapy or radiation in certain regimens to support immune function. Endpoints are usually surrogate (lymphocyte recovery, infection rates) rather than survival.
What does the research NOT show?
This part matters, because the gap between what the evidence supports and what gets sold is where the trouble lives.
- That Thymosin Alpha-1 is a general “immune booster” for healthy adults. The trials enroll patients with impaired immune function, not healthy people looking for an edge.
- That it prevents infection in a generally healthy population. There is no published human evidence for that claim.
- That it has a longevity or anti-aging effect on human lifespan. Zero human trials test that endpoint.
- That it eliminates chronic hepatitis B at the population level. The endpoint is sustained virologic response in a subset of patients, not viral eradication.
- That it is interchangeable with other thymic peptides marketed under similar-sounding names. It is not.
Known safety signals in humans
Across the published trials, Thymosin Alpha-1 has a generally clean tolerability profile. The most commonly reported adverse events are mild local site reactions (redness, transient soreness at the administration site) and a low rate of headache or fatigue. Serious adverse events attributed to the peptide are rare in the published literature.
That clean profile is part of why it carries international approvals. Regulators in 35+ countries reviewed the safety dossier and signed off. That is not a small bar. It is also not the same as the FDA’s bar, which has not been cleared.
The caveat I would want anyone reading this to hold: “well tolerated in trials” describes the patient populations the trials enrolled. Most were patients with chronic infection or immune compromise, monitored in clinical settings. The safety inference does not automatically transfer to a healthy adult using a research-chemical-grade copy in a non-clinical setting.
FDA and legal status
Not FDA approved. No US marketing authorization for any indication. SciClone has not pursued a US filing for Zadaxin to date.
Approved in 35+ countries, including much of Europe, parts of Asia, and Latin America. Indications vary by country: chronic hepatitis B is the most common, with cancer adjuvant and immune-compromised settings added in some markets.
Has appeared on US compounding pharmacy lists historically. Compounding eligibility for any non-FDA-approved active ingredient is narrow and has tightened in 2025 to 2026 as the FDA reviewed several peptides under docket FDA-2025-N-6895. Thymosin Alpha-1 was not on the July 2026 PCAC peptide review list, but the regulatory environment is moving.
Not a controlled substance. The legal exposure runs through how the material is sold and labeled, not personal possession. WADA: prohibited at all times under S2 (peptide hormones, growth factors).
The peculiar position of Thymosin Alpha-1 in the United States is worth saying out loud. It is an approved drug in much of the world, with a generic international name, sold under a brand by a publicly traded company. Inside the US it has no approved status, but it has been quietly available through compounding pharmacies for years and is more familiar to peptide-prescribing clinicians than the average gray-market molecule. The result is a strange middle ground: more legitimate than research chemicals, less legitimate than a prescription drug, with the regulatory definition of where it actually sits depending on which decade and which compounding rules apply.
I built a doctor visit-prep one-pager specifically for the Thymosin Alpha-1 conversation. Evidence summary, side effect questions, and what to ask before considering it. Free PDF. No upsell.
Get the Thymosin Alpha-1 visit-prep one-pagerHow to evaluate a source: the safety framework
Why this section exists: people are going to look for sources whether I help or not. My goal here is harm reduction, not facilitation. I do not name sellers. I do not link to anyone. I am teaching you how to think about a source so you can have an informed conversation with a clinician.
Green flags
- A clinician who knows the international approval context and has actually read at least one Phase 3 publication on the peptide
- A licensed 503A compounding pharmacy with current sterile-compounding accreditation
- Independent third-party testing of identity, purity, and sterility, with a recent certificate of analysis
- A clinician willing to say “this is not a fit for you” and walk away from the conversation
- Disclosure of where the active ingredient is synthesized and which excipients are used
Red flags
- “Research use only” labeling on a vial that is being marketed for human use
- Marketing copy that pitches it as a general “immune booster” for healthy adults
- Claims of efficacy in indications with no published human evidence (longevity, infection prevention in healthy adults, “anti-aging”)
- Refusal or inability to provide independent third-party lab testing
- Confusion or vagueness about which thymic peptide is actually in the vial (Thymosin Alpha-1 is not the same as Thymosin Beta-4 or thymulin)
The wrinkle for Thymosin Alpha-1 specifically
The international-approval story is a double-edged thing. On one hand, the safety dossier is real and regulators have reviewed it. On the other hand, the international product (Zadaxin, made by SciClone) is not what is in most US compounding vials. The molecule on paper is the same. The supply chain, the synthesis, and the quality control are not. That distinction matters and is easy to gloss over in a sales conversation.
Cost reality
Zadaxin internationally is a brand-name biologic with brand-name pricing. The compounded equivalents in the US run cheaper but vary widely in quality. The price gap between the international branded version and the US compounded version is real, and it is paid for in supply-chain rigor. If a compounded version is dramatically cheaper than Zadaxin’s international list price, the question to ask is what part of the supply chain is being skipped.
Questions worth asking any source
Where is the active ingredient synthesized? Where is the finished product compounded, and is the facility 503A-licensed and accredited? Who is the prescribing clinician of record? What is the certificate of analysis on this specific lot? A real source has answers to all four. A bad one substitutes marketing copy.
My 503A Source-Safety Checklist is the single most useful tool on this site. Free PDF. No upsell. It is what I use myself.
Download the source-safety checklistMy honest take
This section is opinion, not evidence. I am not endorsing use of this peptide. Everything above this line is sourced from published human research and regulatory documents. Everything below is my personal perspective as one pseudonymous reader and user. It is not medical advice. Your situation is not my situation. Do not treat this as a recommendation to try anything.
I have not used Thymosin Alpha-1. I do not have a personal anecdote to share, and I would not invent one. What I have is a careful read of the literature and an opinion about why this peptide sits where it sits.
“The most evidence-rich immune peptide in the world is also the quietest one. That is not a coincidence. Boring data does not sell newsletters.”
My read of the gap between the evidence base and the public conversation is mostly about marketability. The trials that earned the international approvals are in patients with chronic infection or immune compromise. They are not in healthy thirty-somethings looking for an edge, and they do not produce the kind of dramatic effect-size soundbite that travels on social media. The result is a peptide that is more legitimate than most of what gets airtime, and gets less airtime because of it.
“If I were going to be skeptical of a peptide pitched as a general immune booster for healthy adults, Thymosin Alpha-1 is the one where the published evidence is least supportive of that pitch, even though the regulatory paper trail is the strongest.”
If a clinician brought it up in the context of a real clinical situation (chronic viral infection, immune compromise, post-treatment immune support), I would take the conversation seriously and read the trials cited. If someone in a wellness Instagram caption pitched it as an immune boost for a healthy adult, I would close the tab. The same molecule looks very different depending on the population it is being offered to.
Questions to ask your doctor
If a clinician is recommending Thymosin Alpha-1, here are the questions I would want answered before agreeing to anything, in order.
- What clinical indication are you considering this for, and is there published human RCT evidence in that specific indication? Chronic hepatitis B is the strongest evidence base. Other indications vary widely in support. The answer should name the trial, not vibes.
- Are you using the internationally approved branded product, or a US compounded version? If compounded, which 503A pharmacy, which lot, and what is the certificate of analysis. The answer matters more than the molecule’s name on paper.
- What is your stop condition? What outcome would cause you to discontinue, and how would you measure it? Asking this question filters out clinicians who do not actually have a clinical model in mind.
- How will we monitor for adverse events? The published trials show good tolerability, but a written monitoring plan beats a vague “let me know if anything happens.”
- Do I actually have a clinical situation that the published evidence applies to? If the honest answer is “no, but it might help anyway,” that is worth knowing.
- What is the realistic expected effect size, and over what timeframe? A clinician who has read the literature should be able to answer this in one sentence with a number.
I built a peptide-specific visit-prep packet to take into your appointment. Evidence summary, doctor questions, space for notes. Free PDF.
Get the visit-prep packetWhat to do next
If you are curious
Read the chronic hepatitis B Phase 3 work directly. The international approval rests on it, and the evidence reads better when you see the actual numbers rather than a summary.
Browse the peptide monographs →If you are considering
Have the conversation with a clinician who can name the trials and explain what indication they are considering. Bring the visit-prep packet. Bring your stop condition before you start.
Get the visit-prep packet →If you have decided
Use the source-safety checklist to evaluate the supply chain. With Thymosin Alpha-1 specifically, the gap between the international branded product and the US compounded version is the part to scrutinize.
Download the source-safety checklist →Sources
- Yang YF, et al. Long-term efficacy of thymosin alpha-1 in HBeAg-positive chronic hepatitis B: a meta-analysis. Antivir Ther. 2008;13(4):489-499. Independent academic analysis pooling industry-funded trials.
- Andreone P, et al. A randomized controlled trial of thymosin alpha-1 versus interferon alfa for chronic hepatitis B. Hepatology. 1996;24(4):774-777. Industry funded (SciClone).
- Chien RN, et al. Efficacy of thymosin alpha-1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology. 1998;27(5):1383-1387. Industry funded.
- Liu F, et al. The effects of thymosin alpha-1 on patients with severe sepsis: a multicenter randomized controlled trial. Crit Care. 2013;17(1):R8. Mixed funding.
- Wu J, et al. Thymosin alpha-1 in patients with severe COVID-19: a multicenter retrospective cohort. Clin Infect Dis. 2020. Observational, mixed funding.
- Goldstein AL, Goldstein AL Jr. From lab to bedside: emerging clinical applications of thymosin alpha-1. Expert Opin Biol Ther. 2009;9(5):593-608. Review article, author conflicts disclosed.
- Italian Medicines Agency (AIFA), European Medicines regulatory documentation for Zadaxin marketing authorizations.
- SciClone Pharmaceuticals, Zadaxin prescribing information (international markets).
Industry funding runs through much of the Phase 3 work, which is normal for a drug developed by a single sponsor. The independent meta-analyses and academic reviews are how I cross-checked the magnitude of effect. Industry funding does not invalidate data; it shapes how the data should be read.
Related monographs
TB-500 / Thymosin Beta-4
The other thymic peptide. Different molecule, different evidence base, much more talked about.
BPC-157
The healing peptide that has zero published human RCTs. The contrast with Thymosin Alpha-1 is instructive.
Semax
Another regionally approved peptide with a serious human evidence base outside the US.
The Peptide File provides educational content based on published research. This article is not medical advice. The Peptide File does not sell, distribute, or facilitate the purchase of any peptide compound. Always work with a qualified healthcare provider.